TG-1042 is under clinical development by Ascend Biopharmaceuticals and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell Carcinoma (Basal Cell Epithelioma) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TG-1042’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TG-1042 overview
TG-1042 (ASN-002) is under development for the treatment of basal cell carcinoma, relapsing primary cutaneous B-cell lymphomas and nodular basal cell carcinoma, cutaneous head and neck squamous cell carcinoma, basal cell carcinoma in patients with gorlin syndrome. It is administered by intratumor injection. TG-1042 is a recombinant adenovirus encoding the human immunoregulatory cytokine interferon gamma (IFNgamma).
It was also under development for the treatment of metastatic melanoma, cutaneous B-cell lymphoma, recurrent ovarian cancer and cutaneous T cell lymphoma.
For a complete picture of TG-1042’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
